Spineway Reports 4% Revenue Growth in 2025 and Enhances Profitability
Spineway Group concluded the 2025 fiscal year with an annual revenue of 12.4 million euros, marking a 4% increase despite regulatory and logistical hurdles. Profitability has improved while cash reserves remained stable at 3.5 million euros.
Challenges Overcome and Strategic Advances
As a specialist in innovative implants for the treatment of spinal disorders, Spineway recorded an annual revenue of 12.4 million euros in 2025, up by 4% compared to the previous year. This growth occurred despite several operational challenges: delays in certifications in Latin America, tender award delays in Asia, and supply tensions. Throughout the year, the group consolidated its geographical diversification, launched its new ESP1 disc prosthesis production line, and continued its regulatory investments. Gross margin reached 8.6 million euros, representing 69.6% of the revenue, an improvement of 0.6 points from 2024. Net operating costs increased by 5% on a proforma basis, a rate aligned with sales growth but marked by sustained regulatory expenses in certification and clinical studies.
Stable Operating Results and Financial Improvements
Operating income remained stable at minus 2.1 million euros, compared to minus 2 million euros in 2024 (proforma data). The major improvement came from the reduction of financial expenses: the bond financing contract with Negma concluded in May 2025 without penalty, generating savings of 2.1 million euros. Research and innovation tax credits returned to 149,000 euros after an exceptional level last year. Consequently, the net result improved by 1.6 million euros, settling at minus 2.2 million euros. The group's financial debt decreased by 0.3 million euros to 1.5 million euros, while net cash stood at 2 million euros compared to 2.7 million euros a year earlier. External financing through bond issues was limited to 0.4 million euros in 2025, compared to 6.8 million euros in 2024, with overall cash consumption limited to 1 million euros for the year.
Leveraging Synergies and Focusing on Growth
Since 2021, leveraging synergies from the acquisitions of Distimp and Spine Innovation has nearly tripled the group's consolidated revenue. Spineway plans to continue its investments in regulatory affairs, marketing, and research and development, relying on disciplined operational management to consolidate its growth potential. The group has a global network of over 50 independent distributors and generates more than 70% of its revenue from exports.
